List of Excipients in Branded Drug LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

« Back to Dashboard

Generic Drugs Containing LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

Company	Ingredient	NDC	Excipient
IQ Dental	lidocaine hydrochloride and epinephrine bitartrate	42756-1030	EDETATE DISODIUM
IQ Dental	lidocaine hydrochloride and epinephrine bitartrate	42756-1030	POTASSIUM METABISULFITE
IQ Dental	lidocaine hydrochloride and epinephrine bitartrate	42756-1030	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE?

# Of NDCs	Excipient
2	EDETATE DISODIUM
2	POTASSIUM METABISULFITE
2	SODIUM CHLORIDE

Last updated: October 1, 2026

ecutive summary: Lidocaine hydrochloride and epinephrine bitartrate is a mature, generic injectable combination with limited composition-of-matter or exclusivity protection. Commercial value depends on formulation execution, packaging, preservative status, concentration, route-specific usability, supply reliability, and device integration. The strongest opportunities are preservative-free dental cartridges, ready-to-use syringes, low-volume procedural formats, and differentiated presentations that reduce preparation errors and epinephrine oxidation. Patent barriers are generally weak, while regulatory, sterility, container-closure, and manufacturing controls remain the main entry barriers.

Lidocaine Hydrochloride and Epinephrine Bitartrate Excipient Strategy and Commercial Opportunities

What is the commercial role of lidocaine hydrochloride and epinephrine bitartrate?

Lidocaine hydrochloride provides local anesthesia by blocking sodium channels. Epinephrine produces local vasoconstriction, which can prolong anesthesia and reduce systemic absorption and procedural bleeding. The combination is used in dental anesthesia, local infiltration, nerve blocks, minor surgery, dermatology, otolaryngology, and other procedural settings.

Commercial products typically use lidocaine concentrations of 1% or 2% with epinephrine concentrations expressed as 1:100,000 or 1:200,000. The epinephrine component is often identified on labeling as epinephrine bitartrate, with the strength expressed in terms of epinephrine equivalent. Product presentations include dental cartridges, vials, ampules, and prefilled syringes.

The market is mature. Generic manufacturers compete primarily on:

• Cost and manufacturing scale
• Reliable supply of sterile injectable product
• Cartridge and syringe compatibility
• Preservative-free or low-excipient formulations
• Shelf life and oxidation control
• Concentration and presentation breadth
• Hospital, dental, and ambulatory surgery contracts

FDA-approved products are generally regulated as injectable local anesthetics under the drug approval and generic drug pathways. The combination has no biosimilar component because both active ingredients are small molecules, not biologics.

What excipients are used in lidocaine and epinephrine injections?

The central excipient problem is epinephrine instability. Epinephrine is susceptible to oxidation, light exposure, oxygen, elevated pH, and trace-metal catalysis. The formulation must preserve potency and appearance while maintaining lidocaine solubility, acceptable osmolality, sterility, and injection-site tolerability.

Excipient or formulation element	Primary function	Commercial and technical considerations
Sodium metabisulfite or sodium bisulfite	Antioxidant protection for epinephrine	Commonly used; requires sulfite labeling and hypersensitivity warnings
Sodium chloride	Tonicity adjustment	Supports injection tolerability; concentration must be balanced against total osmolality
Hydrochloric acid or sodium hydroxide	pH adjustment	Controls stability, solubility, and injection performance
Water for Injection	Vehicle	Must meet parenteral water and sterility requirements
Nitrogen headspace or low-oxygen filling	Reduces oxidative stress	Can support shelf life and color control
Preservatives such as methylparaben	Multidose microbial protection	May be unsuitable for certain routes, pediatric use, or premium preservative-free positioning
Chelating agents	Trace-metal control	Potentially useful in specialized development but must be justified for injectable use and regulatory acceptance

Not every commercial product contains every listed excipient. The formulation must be evaluated against the intended presentation. A single-dose dental cartridge has different requirements from a multidose vial or a prefilled syringe.

How should sodium metabisulfite be evaluated?

Sodium metabisulfite is a practical antioxidant for epinephrine-containing formulations. Its main disadvantages are regulatory labeling, sulfite sensitivity concerns, and possible market resistance in patient populations with asthma or documented sulfite sensitivity. FDA labeling for epinephrine-containing local anesthetics includes warnings concerning sulfite reactions, particularly in susceptible patients. [1,2]

A developer seeking differentiation can pursue:

1. Lower sulfite concentration supported by stability data.
2. Alternative oxygen-control strategies.
3. Improved container-closure systems.
4. Nitrogen purging and low-oxygen filling.
5. A preservative-free, single-use presentation that minimizes microbial risk.
6. A dual-market portfolio with standard sulfite-containing and premium low-excipient products.

A lower-antioxidant formulation is not automatically superior. Epinephrine potency, impurity growth, color, pH drift, and extractables must remain within specification through the proposed shelf life.

Which formulation strategies create the strongest commercial opportunities?

Preservative-free dental cartridges

Dental cartridges are one of the most attractive segments because dentists value immediate availability, predictable needle and cartridge compatibility, and reduced preparation time. Common commercial strengths include 2% lidocaine with epinephrine 1:100,000 or 1:200,000.

A differentiated dental product could offer:

• Glass or polymer cartridges compatible with major aspirating syringes
• Low extractables and low adsorption packaging
• Clear identification of epinephrine concentration
• Improved break resistance
• Reliable plunger movement
• Reduced particulate and discoloration risk
• Longer validated shelf life
• Small-volume cases for high-throughput dental practices

The formulation should avoid unnecessary preservatives in a single-use cartridge. The primary intellectual property opportunity is more likely to involve cartridge geometry, closure systems, oxygen-control methods, filling processes, or device compatibility than the active ingredients themselves.

Ready-to-use syringes

Ready-to-use syringes can reduce drawing errors and support emergency departments, operating rooms, ambulatory surgery centers, and office-based procedures. The commercial advantages are dose consistency, shorter preparation time, and lower risk of contamination during transfer.

Key development issues include:

• Syringe material compatibility
• Silicone oil and particulate control
• Tip-cap integrity
• Plunger break-loose and glide forces
• Light protection
• Epinephrine adsorption or oxidation
• Compatibility with automated administration systems
• Label differentiation between 1:100,000 and 1:200,000

A ready-to-use syringe may qualify for a differentiated regulatory strategy if it changes the dosage form, container system, or administration method in a way that requires new clinical, device, or human-factors data. A conventional generic syringe presentation would ordinarily rely on an ANDA pathway if equivalence can be established.

Low-volume procedural products

Low-volume vials and ampules can serve dermatology, emergency medicine, minor surgery, and office-based procedures. The main opportunity is operational convenience rather than active-ingredient differentiation.

A portfolio can combine:

• 1% lidocaine with epinephrine
• 2% lidocaine with epinephrine
• 1:100,000 epinephrine
• 1:200,000 epinephrine
• Single-dose and multidose formats
• Preservative-free and standard presentations

The products should be designed around common procedural dosing and minimize the need for dilution or bedside mixing.

What FDA regulatory pathways apply to this combination?

The relevant pathway depends on whether the product is a conventional generic or a materially differentiated presentation.

Product strategy	Likely pathway	Main regulatory burden
Same strength, route, dosage form, and inactive-ingredient profile as reference product	ANDA under section 505(j)	Pharmaceutical equivalence, bioequivalence where applicable, chemistry, manufacturing, and controls
New container or delivery system with clinical or human-factors differences	Potential 505(b)(2) NDA	Bridge to reference product plus formulation, device, or clinical support
Novel preservative-free formulation	ANDA or 505(b)(2), depending on differences	Stability, sterility, justification of inactive ingredients, route-specific safety
New indication or materially different concentration	505(b)(2) or supplemental approval	Clinical justification and labeling support
Hospital-ready prefilled device	ANDA or 505(b)(2) with combination-product considerations	Device performance, human factors, container closure, administration reliability

FDA-approved labeling identifies the active ingredients, concentrations, contraindications, warnings, and excipients for each product. DailyMed labeling should be reviewed product by product because inactive ingredients and presentations differ between manufacturers. [1,2]

FDA’s Inactive Ingredient Database can help assess precedent for excipients and routes of administration, but precedent does not eliminate the need for product-specific safety, stability, and manufacturing data. [3]

What patents protect lidocaine hydrochloride and epinephrine bitartrate products?

The active ingredients are old and do not have meaningful current composition-of-matter exclusivity. Commercial protection is more likely to arise from:

• Specific container-closure systems
• Prefilled syringe construction
• Dental cartridge components
• Oxygen-reduction filling methods
• Stabilized epinephrine formulations
• Novel concentration combinations
• Manufacturing controls that produce improved impurity profiles
• Method-of-use claims tied to a particular procedural setting

What is the Orange Book status of the combination?

The FDA Orange Book is the principal source for approved drug products, therapeutic-equivalence evaluations, patent listings, and regulatory exclusivity information. [4] Mature lidocaine-epinephrine products generally compete as multisource generics, and the market does not depend on a currently enforceable pioneer patent covering the active combination.

Protection category	Commercial assessment
Lidocaine composition-of-matter patent	Expired
Epinephrine composition-of-matter patent	Expired
Combination patent covering ordinary injectable use	No meaningful blocking protection expected for mature products
Regulatory exclusivity	Generally absent for established generic presentations
Formulation patents	Possible for specialized products, but not inherent to the conventional combination
Device or packaging patents	Possible and commercially relevant
Method-of-use patents	Possible but limited value if use is established and claims are narrow

A transaction or launch analysis should check the current Orange Book and relevant patent records for the exact reference product, dosage form, and presentation. The existence of a formulation or device patent does not necessarily block an ANDA if the patent is not listed, expired, or can be addressed through a paragraph IV certification.

When does lidocaine and epinephrine lose exclusivity?

The underlying drug combination is already in the post-exclusivity generic market. The practical entry question is not loss of basic exclusivity but whether a particular manufacturer has a product-specific patent, regulatory exclusivity period, or market position that delays competition.

What paragraph IV challenges are relevant?

A paragraph IV certification is generally relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. For a mature lidocaine hydrochloride and epinephrine bitartrate injection, paragraph IV activity is likely to concern a specialized formulation, presentation, or device rather than the conventional active combination.

Potential paragraph IV targets could include:

• Stabilized epinephrine compositions
• Novel preservative systems
• Prefilled syringe formats
• Cartridge or closure technology
• Extended shelf-life claims
• New concentration or administration systems

A paragraph IV strategy has limited value where the target product has no current listed patent or where the commercial product can be designed around the claimed feature.

What patent litigation and settlement agreements affect the market?

The combination does not have the litigation profile associated with high-value branded small molecules or biologics. There is no inherent biosimilar litigation pathway, and conventional generic competition is already established.

The main litigation risks are likely to involve:

• ANDA litigation over a specialized formulation
• Device or cartridge patents
• Trade-secret disputes involving sterile filling or packaging
• Contract manufacturing and supply agreements
• Product liability claims relating to dosing, labeling, or sulfite sensitivity
• Antitrust or exclusivity disputes involving hospital contracts

Settlement agreements are most commercially relevant if a branded or specialty product has an unexpired formulation or device patent. For standard lidocaine-epinephrine injections, the expected settlement value is limited because multiple generic alternatives exist.

How strong is the patent estate for lidocaine hydrochloride and epinephrine bitartrate?

The patent estate is weak for the active combination and potentially moderate for differentiated delivery systems.

Asset type	Patent strength	Commercial value
Conventional 1% or 2% injectable combination	Low	Limited exclusivity; price competition
Conventional dental cartridge	Low to moderate	Value depends on packaging and supply reliability
Preservative-free formulation	Moderate if technically differentiated	May support premium pricing and institutional contracts
Ready-to-use syringe	Moderate	Device and formulation claims can create barriers
Long-shelf-life, oxidation-controlled product	Moderate	Requires strong comparative stability data
Novel administration system	Moderate to high	Potential 505(b)(2) and device protection
New indication	Case-specific	Dependent on clinical differentiation and claim breadth

Strong claims would need to cover measurable technical advantages, such as improved stability, reduced degradation, lower oxygen exposure, enhanced container compatibility, or administration reliability. Broad claims covering lidocaine, epinephrine, and routine injectable excipients would face substantial validity and design-around risk.

What generic launch scenarios exist?

Commodity generic launch

A manufacturer launches conventional vial or cartridge products matching established strengths. This approach has the shortest development path but the highest price pressure.

Dental-focused portfolio launch

The company launches multiple cartridge strengths with strong packaging, dependable supply, and broad distributor coverage. This strategy can support share gains even without patent protection.

Premium preservative-free launch

The company targets hospitals, ambulatory surgery centers, and clinicians seeking lower-excipient products. Pricing depends on documented clinical or operational advantages and reliable availability.

Ready-to-use syringe launch

The product targets medication-error reduction and operating-room efficiency. It requires greater investment in device performance, human factors, packaging, and manufacturing validation.

Contract-manufactured regional launch

A company can use an established sterile injectable manufacturer to enter selected countries or institutional markets. The main risks are capacity allocation, quality agreements, technology transfer, and supply continuity.

Which companies and products compete with lidocaine and epinephrine?

Competition includes generic injectable manufacturers, dental anesthetic suppliers, specialty sterile injectables companies, and branded local-anesthetic providers. The relevant competitive set includes:

• Generic lidocaine with epinephrine injections
• Branded Xylocaine with epinephrine products
• Articaine with epinephrine for dentistry
• Mepivacaine formulations, often without vasoconstrictor
• Bupivacaine with or without epinephrine
• Ropivacaine products
• Alternative local anesthetic delivery systems

Articaine with epinephrine is particularly relevant in dentistry because it competes directly for dental cartridge demand. Bupivacaine and ropivacaine compete in procedures requiring longer-duration anesthesia, while plain lidocaine or mepivacaine competes where vasoconstrictor exposure is undesirable.

What manufacturing and intellectual-property barriers matter most?

The largest barriers are operational rather than patent-based.

Critical controls include:

• Sterile manufacturing and aseptic processing
• Epinephrine oxidation control
• Low-oxygen filling
• Light-protective packaging
• Container-closure integrity
• Extractables and leachables
• Particulate control
• Dose uniformity
• Cartridge and syringe functionality
• Stability-indicating analytical methods
• Supplier qualification for active ingredients and excipients

A manufacturer with validated cartridge filling, reliable sterile capacity, and strong quality systems can achieve a meaningful market position without owning a blocking patent.

What is the revenue exposure and commercial outlook?

Revenue exposure is generally linked to procedure volume rather than chronic-patient adherence. Demand is distributed across dental offices, hospitals, ambulatory surgery centers, emergency departments, outpatient clinics, and office-based procedural practices.

The commercial outlook is strongest where a product reduces workflow friction:

• No bedside dilution
• No vial-to-syringe transfer
• Clear concentration differentiation
• Fewer preservative concerns
• Lower product waste
• Reliable availability
• Compatible packaging
• Consistent shelf life

A conventional generic product is likely to face low margins. A differentiated cartridge, prefilled syringe, or oxygen-controlled formulation can support better pricing, but only if the product produces measurable operational value and avoids manufacturing complexity that destroys gross margin.

Key takeaways

• Lidocaine hydrochloride and epinephrine bitartrate is a mature generic combination with no meaningful active-ingredient exclusivity.
• Sodium metabisulfite, pH control, oxygen management, and packaging are central excipient and stability issues.
• Preservative-free dental cartridges and ready-to-use syringes offer the clearest commercial differentiation.
• Patent value is concentrated in formulations, container systems, delivery devices, and manufacturing processes.
• Conventional products are likely to compete primarily on price, availability, and quality performance.
• No biosimilar risk applies because the combination contains small-molecule active ingredients.
• Regulatory, sterility, stability, and container-closure requirements are more important entry barriers than composition-of-matter patents.
• The strongest launch strategy is a focused portfolio built around common concentrations, robust packaging, and reliable sterile supply.

FAQs

Is epinephrine bitartrate the same as epinephrine in local anesthetic products?

Epinephrine bitartrate is a salt form used to formulate epinephrine. Product labeling generally expresses the clinical concentration in terms of epinephrine, such as 1:100,000 or 1:200,000.

Can a preservative-free lidocaine-epinephrine product command a premium price?

It can support premium positioning in selected hospital, dental, and procedural markets, but pricing depends on documented stability, sterility assurance, packaging performance, and supply reliability.

Which concentration is more commercially attractive, 1:100,000 or 1:200,000?

Both have established demand. The 1:100,000 strength is widely used when stronger vasoconstriction is desired, while 1:200,000 can appeal to users seeking lower epinephrine exposure. A commercial portfolio should generally include both where manufacturing economics support it.

Can a new excipient combination receive patent protection?

Yes, if the formulation produces a non-obvious and measurable technical result, such as improved epinephrine stability, reduced degradation, improved container compatibility, or enhanced shelf life. Routine substitution of known injectable excipients is unlikely to produce strong patent protection.

What is the most defensible commercial differentiation for this product?

The most defensible differentiation is usually a combination of validated oxidation control, preservative-free single-use packaging, reliable cartridge or syringe performance, and workflow benefits supported by regulatory and stability data.

References

1. DailyMed. (n.d.). Lidocaine hydrochloride and epinephrine injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Xylocaine and lidocaine hydrochloride with epinephrine labeling. FDA Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book